FDA – Page 4 – medicarereport.org

Thursday, November 21, 2024

Latest:

FDA Legislative Update Part D/Prescription Drugs

Eileen Cook December 7, 2023December 7, 2023 Drug Imports, Drugmakers, FDA, Medicare Part D

Colorado Blames Biden Team and Drugmakers for Delaying Canadian Imports

(By Phil Galewitz for KFF Health News) Colorado officials say their plan to import cheaper medicines from Canada has been

Aging FDA Legal Actions/Court Decisions Medical Technology

Eileen Cook December 5, 2023 Artificial Hips, FDA, Healthcare Costs, Medical Technology, Older Adults

Patients Expected Profemur Artificial Hips to Last. Then They Snapped in Half.

(By Brett Kelman and Anna Werner, CBS News and KFF Health News) Bradley Little, a physical education teacher in Arizona,

Alzheimer's/Dementia FDA Medicare - General Part D/Prescription Drugs

Eileen Cook November 28, 2023November 28, 2023 Aducanumab, Alzheimer's Disease, ARIA, CMS, Dementia, Donanemab, FDA, Lecanemab Drug, medicare, Medicare Part D, Older Adults

Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect

(By Madhav Thambisetty for STAT) Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision to cover

Aging Alzheimer's/Dementia FDA Medicare - General

Eileen Cook August 11, 2023August 11, 2023 0 Comments Alzheimer's Disease, Alzheimer's Treatment, Donanemab, FDA, Leqembi, medicare

New Alzheimer’s Drug Raises Hopes — Along With Questions

(By Judith Graham for KFF Health News) The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer’s and

FDA Veterans Benefits

Eileen Cook August 8, 2023August 8, 2023 0 Comments ALS, FDA, Lou Gehrig’s disease, Qalsody, Veterans, Veterans Health care

New ALS medication offers hope

(Source – news.va.gov) A Marine Corps Veteran got an infusion of hope this week when he became the second patient

FDA Health Care Finance Legislative Update Part D/Prescription Drugs

Eileen Cook August 4, 2023August 4, 2023 0 Comments FDA, Healthcare Costs, Inflation Reduction Act of 2022, Prescription drug costs

KFF Health Tracking Poll July 2023: The Public’s Views Of New Prescription Weight Loss Drugs And Prescription Drug Costs

(By Alex Montero, Grace Sparks, Ashley Kirzinger, Isabelle Valdes, and Liz Hamel for Kaiser Family Foundation Published: Aug 04, 2023)

Alzheimer's/Dementia Health Care Finance Medicaid Medicare - General Part D/Prescription Drugs

Eileen Cook August 2, 2023August 2, 2023 0 Comments Alzheimer's Disease, CMS, Donanemab, Dual Eligible, FDA, Lecanemab Drug, Medicaid, medicare, Medicare Part D, Older Adults

The Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers

(By Arthur Allen for KFF Health News) The first drug purporting to slow the advance of Alzheimer’s disease is likely

Alzheimer's/Dementia FDA Part D/Prescription Drugs

Eileen Cook July 18, 2023July 18, 2023 0 Comments Alzheimer's Disease, Donanemab, FDA, Medicare Part D, Older Adults

An experimental Alzheimer’s drug outperforms one just approved by the FDA

(By Jon Hamilton for NPR) Patients in the early stages of Alzheimer’s may soon have a new option to stave

Alzheimer's/Dementia CMS FDA Part D/Prescription Drugs

Eileen Cook July 10, 2023July 10, 2023 0 Comments Alzheimer's Disease, CMS, FDA, Lecanemab Drug, Medicare Part D

Statement: Broader Medicare Coverage of Leqembi Available Following FDA Traditional Approval

(Source – www.cms.gov/newsroom) Broader Medicare coverage is now available for Biogen and Eisai’s Leqembi (the brand name for lecanemab) following

Alzheimer's/Dementia CMS FDA Medicare - General Part D/Prescription Drugs

Eileen Cook June 26, 2023June 26, 2023 0 Comments Aducanumab, Alzheimer's Disease, CMS, FDA, Lecanemab Drug, medicare, Older Adults

An Alzheimer’s drug is on the way, but getting it may still be tough. Here’s why

(By Jon Hamilton for NPR) The first drug shown to slow down Alzheimer’s disease is likely to receive full approval